<DOC>
	<DOCNO>NCT02842931</DOCNO>
	<brief_summary>Purpose : evaluate efficacy chemotherapy regimens R-DA-EPOCH-21 R-mNHL-BFM-90 without autologous hematopoietic stem cell transplantation ( auto-SCT ) newly diagnose patient DLBCL intermediate high risk .</brief_summary>
	<brief_title>R-Dose-adjusted ( DA ) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma ( NHL ) -Berlin-Frankfurt-Munster ( BFM ) -90 Program ( mNHL-BFM-90 ) Autologous Stem Cells Transplantation ( Auto-SCT ) DLBCL With Poor Prognosis</brief_title>
	<detailed_description>Patients initially randomize 4 arm : 1. st arm R-DA-EPOCH-21 2. nd arm R-mNHL-BFM-90 3. rd arm R-DA-EPOCH-21 + auto-SCT 4. th arm R-mNHL-BFM-90 + auto-SCT Patients achieve complete remission 6 cycle R-DA-EPOCH-21 R-mNHL-BFM-90 immunochemotherapy continue observation ( 1st 2nd arm ) continue treatment Rituximab + BCNU+Etoposid+Ara-C+Melphalan ( R-BEAM ) follow auto-SCT ( 3rd 4th arm ) . Patients achieve partial remission 6 cycle R-DA-EPOCH-21 R-mNHL-BFM-90 immunochemotherapy continue treatment 2 cycle Rituximab+Dexamethasone+Ara-C+Cisplatin ( R-DHAP ) , continue observation ( 1st 2nd arm ) continue treatment R-BEAM , follow auto-SCT ( 3rd 4th arm ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>1 . Newly diagnose DLBCL , 2 . No previous treatment chemotherapy and/or radiation therapy DLBCL 3 . Presence 2 sign unfavorable prognosis ( IPI 24 ) 4 . Age 1860 year . 1 . Transformation mature cell lymphomas DLBCL . 2 . Bcell lymphoma , unclassifiable , feature intermediate DLBCL Hodgkin 's lymphoma 3 . Bcell lymphoma , unclassifiable , feature intermediate DLBCL Burkitt lymphoma 4 . DLBCL central nervous system ( CNS ) 5. testicular DLBCL 6 . Primary mediastinal large Bcell lymphoma 7 . Pretreated DLBCL . 8 . HIVassociated DLBCL 9 . Congestive heart failure , unstable angina , severe cardiac arrhythmia conduction disturbance , myocardial infarction . 10 . Renal insufficiency ( serum creatinine great 0.2 mmol/L ) ( except case specific kidney infiltration , urinary tract compression tumor conglomerate presence uric acid nephropathy due massive cytolysis syndrome ) . 11 . Liver failure ( except case liver tumor infiltration ) , acute hepatitis active phase chronic hepatitis B C serum bilirubin great 1.5 standard , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) great 3 standard , prothrombin index less 70 % . 12 . Severe pneumonia ( except case specific lung infiltration ) , accompany respiratory failure ( dyspnea &gt; 30 min. , hypoxemia le 70 mm Hg , impossible compensate situation 23 day ) . 13 . Lifethreatening bleeding ( gastrointestinal , intracranial ) , exception bleeding due tumor infiltration organ ( stomach , intestine , uterus , etc . ) disseminate intravascular coagulation due underlie disease complication successful conservative treatment . 14 . Severe mental disorder ( delusion , severe depressive syndrome manifestation productive symptom ) relate specific infiltration central nervous system . 15 . Decompensated diabetes . 16 . Pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>DLBCL , R-DA-EPOCH-21 , R-mNHL-BFM-90 , auto-SCT</keyword>
</DOC>